{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:54:11Z","timestamp":1793091251748,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.vaccine.2013.04.063","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T03:12:32Z","timestamp":1368155552000},"page":"3051-3058","source":"Crossref","is-referenced-by-count":65,"title":["Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers"],"prefix":"10.1016","volume":"31","author":[{"given":"Robert J.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy F.","family":"Daczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina E.","family":"Kaptur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Muse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sheldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"LaForce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suha","family":"Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Rudge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Bernton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.vaccine.2013.04.063_bib0005","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax\u00ae (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.04.063_bib0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0264-410X(99)00316-3","article-title":"Comparison of the effect of different immunological adjuvants on the antibody and T-cell reponse to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines","volume":"18","author":"Kim","year":"1999","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2013.04.063_bib0015","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.4049\/jimmunol.164.11.5683","article-title":"CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo","volume":"164","author":"Segal","year":"2000","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2013.04.063_bib0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/CVI.00420-07","article-title":"Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CPG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques","volume":"15","author":"Stewart","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.04.063_bib0025","series-title":"BioThrax\u00ae prescribing information","year":"2012"},{"key":"10.1016\/j.vaccine.2013.04.063_bib0030","series-title":"Investigational brochure AV7909 Anthrax Vaccine. Version 3","year":"2012"},{"issue":"6","key":"10.1016\/j.vaccine.2013.04.063_bib0035","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/CVI.00003-08","article-title":"Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species","volume":"15","author":"Omland","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"1\/2","key":"10.1016\/j.vaccine.2013.04.063_bib0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2013.04.063_bib0055","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00002371-200411000-00006","article-title":"Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeosynucleotide TLR9 agonist","volume":"27","author":"Krieg","year":"2004","journal-title":"J Immunother"},{"issue":"23-24","key":"10.1016\/j.vaccine.2013.04.063_bib0060","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.vaccine.2004.01.058","article-title":"Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine","volume":"22","author":"Cooper","year":"2004","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2013.04.063_bib0065","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1016\/j.vaccine.2009.10.087","article-title":"A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1\/Alhydrogel+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults","volume":"27","author":"Sagara","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2013.04.063_bib0070","doi-asserted-by":"crossref","first-page":"e2940","DOI":"10.1371\/journal.pone.0002940","article-title":"Phase 1 trial of AMA1-C1\/Alhydrogel plus CPG 7909 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria","volume":"3","author":"Mullen","year":"2008","journal-title":"PLoS ONE"},{"issue":"17","key":"10.1016\/j.vaccine.2013.04.063_bib0075","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-08-0526","article-title":"CpG oligodeoxynucleotides after lymphocyte and dendritic cell trafficking in humans","volume":"14","author":"Haining","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300532X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300532X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T03:52:58Z","timestamp":1539661978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1300532X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":13,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0264410X1300532X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.04.063","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}